Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering

Teva Pharmaceuticals Europe BV, TEVA and MSD MRK today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for NOMAC-E2 an investigational monophasic combined oral contraceptive tablet indicated for the use by women to prevent pregnancy.

NOMAC-E2 is a birth control pill that contains 2 steroid hormones nomegestrol acetate, a highly selective, progesterone-derived progestin and 17-beta estradiol (E2), an estrogen that is similar to the one naturally present in a woman's body. The next step for marketing authorization is review by the European Commission.